- Home
- AGIO
as 11-21-2024 11:30am EST
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.0B | IPO Year: | 2013 |
| Target Price: | $52.33 | AVG Volume (30 days): | 726.4K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.96 - $62.58 | Next Earning Date: | 10-31-2024 |
| Revenue: | $32,871,000 | Revenue Growth: | 36.79% |
| Revenue Growth (this year): | 33.38% | Revenue Growth (next year): | 163.06% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Nov 8 '24 | Sell | $56.09 | 772 | $43,301.48 | 813 | |
| Ballal Rahul D. | AGIO | Director | Nov 7 '24 | Sell | $56.55 | 20,000 | $1,117,146.69 | 7,992 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Sep 26 '24 | Sell | $49.03 | 2,542 | $124,634.26 | 20,158 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News
GlobeNewswire
16 days ago
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Zacks
20 days ago
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Zacks
20 days ago
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Simply Wall St.
20 days ago
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
20 days ago
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
MT Newswires
21 days ago
Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss
Zacks
21 days ago
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.